Quality of life in Prolactinoma: A systematic review
Authors' conclusion
Poor quality of life in prolactinoma is multifactorial, related to biochemical control, side effects of therapy, and sellar mass effect. Targeting persistent symptoms, reducing healthcare costs, and reducing side-effects of therapy are avenues to improving QOL in patients with prolactinoma.
Study context
- Population
- Patients with prolactinoma; studies reporting quality-of-life (QOL) with validated metrics
- Participants
- 877 patients18 studies
- Outcome
- Patient QOL measured with validated metrics
Methodological detailsPRISMA, MINORS risk-of-bias assessment
- PRISMA
- MINORS risk-of-bias assessment
Pooled result
As reported in the abstract
QOL in prolactinoma
- Worse QOL than healthy controls, particularly mental and psychosocial wellbeing
- QOL worse than non-functional adenomas, but better than Cushing's disease and acromegaly
- QOL correlates with prolactin levels and approaches population baseline with prolonged biochemical control
- Dopamine agonists and surgery both improve overall QOL; improvements more rapid with surgery
- Most were small cross-sectional studies at high risk of bias
Original publication
Quality of life in Prolactinoma: A systematic review. Pituitary. Published 24 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →